SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (5029)7/29/1998 7:45:00 PM
From: John Metcalf   of 6136
 
Entremed has a higher nominal share price than Agouron, but less than 40% as many shares. ENMD is trading at a market capitalization of about $385mm, vs. $945mm for AGPH.

I don't mean to imply that these relative valuations are realistic. Agouron's projected FY 99 sales are greater than the difference between the two cap levels, indicating that AGPH' relatively advanced products are valued much lower than ENMD's products which have not yet been tested in people.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News